Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05860374
Other study ID # XYFY-R130-AST
Secondary ID
Status Recruiting
Phase Early Phase 1
First received
Last updated
Start date March 2, 2023
Est. completion date March 2, 2026

Study information

Verified date March 2023
Source Shanghai Yunying Medical Technology
Contact Feng Pan, MD
Phone +8613764868528
Email pf@jxyymedtech.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

20 participants are expected to be enrolled for this open,Single-armed clinical trial to evaluate the safety and efficacy of the recombinant herpes simplex virus Ⅰ, R130 in patients with advanced solid tumors.


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date March 2, 2026
Est. primary completion date March 2, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Patients with solid tumors clearly diagnosed by histology and/or cytology. 2. Failure of standard treatment or patient unwillingness to receive other antitumor therapy. 3. Age 18 to 75 years. 4. Subjects with ECoG score of 0-2. 5. Expected survival of 3 months or more. 6. Have at least one measurable lesion (according to RECIST 1.1 criteria) that is amenable to intratumoral or intraperitoneal drug delivery. 7. Subjects must have appropriate organ function, and laboratory tests during the screening period must meet the following requirements: a) absolute neutrophil count (ANC) = 1.5 × 109/L, platelets (PLT) = 80 × 109/L, and hemoglobin (Hb) = 85 g/L; b) serum creatinine (Cr) and blood urea nitrogen (BUN) within 1.5 times the upper limit of normal values; c) serum c) serum total bilirubin (TBIL) = 2 times the upper limit of normal values; d) glutamic aminotransferase (ALT) and glutamic oxalacetic aminotransferase (AST) = 2.5 times the upper limit of normal values; subjects with liver metastases do not exceed 5 times the upper limit of normal values; e) activated partial thromboplastin time (APTT), prothrombin time (PT) within 1.5 times the upper limit of normal values. 8. No absolute or relative centasis contraindiction. 9. Eligible patients of childbearing potential must agree to use a reliable method of contraception with their partner for the duration of the trial and for at least 180 days after the last dose; female patients of childbearing potential must have a negative urine pregnancy test within 7 days prior to enrollment. 10. Subjects voluntarily sign an informed consent form and are in good compliance. Exclusion Criteria: 1. Have had any serious adverse reactions associated with immunotherapy. 2. Subjects with any severe and/or uncontrolled disease, including: a) poorly controlled hypertension (systolic blood pressure = 150 mmHg or diastolic blood pressure = 100 mmHg); b) suffering from class I or higher myocardial ischemia or myocardial infarction, arrhythmia (QTc = 470 ms and = grade 2 congestive heart failure (New York Heart Association (NYHA) classification); c) active or uncontrolled severe infection (= CTCAE grade 2 infection); d) Patients with previous organ transplantation, bone marrow transplantation (hematopoietic stem cell transplantation) and severe immune deficiency; e) Urine routine suggesting urine protein =++ and confirmed 24-hour urine protein quantification > 1.0 g. 3. Patients with past history of type I diabetes mellitus or HIV. 4. Severe abnormalities in thyroid and cortisol testing; active, known or suspected autoimmune disease requiring systemic therapy. 5. Patients with severe prior interstitial lung changes (as determined by the investigator). 6. Patients with active tuberculosis and a strong positive OT test. 7. Patients with active bleeding or severe coagulation dysfunction. 8. Have had antitumor therapy, including endocrine, chemotherapy, radiotherapy, targeted therapy, immunotherapy and antitumor herbal therapy, 4 weeks prior to the first dose. 9. Have not recovered to CTCAE 4.0 grade rating 0 or 1 level of toxicity after previous antineoplastic therapy. 10. Current active hepatitis B, active hepatitis C, immunodeficiency virus or other active infection of clinical significance. 11. Patients who have undergone surgery of grade 3 or higher or whose surgical wounds have not healed within 4 weeks prior to enrollment. 12. Pregnant, lactating and planning to have children within six months. 13. Subjects who, in the judgment of the investigator, are unsuitable for participation in this trial for any reason.

Study Design


Intervention

Drug:
Recombinant oncolytic herpes simplex virus type 1 (R130)
R130, a modified herpes simplex virus-? (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11

Locations

Country Name City State
China Xuzhou Second People's Hospital Shanghai Jiangsu

Sponsors (2)

Lead Sponsor Collaborator
Shanghai Yunying Medical Technology The Affiliated Hospital of Xuzhou Medical University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Disease Assessment for Duration of Response Evaluate the efficacy endpoints of DOR by the investigator with RECIST v1.1 and iRECIST Every 10 weeks for 12 months
Other Quality of Life Assessment Evaluate with EORTC QLQ-C30 Every 6 weeks for 12 months
Primary Subject incidence of adverse events To characterize the safety profile of R130 injection in patients with advanced solid tumors as measured by the incidence of Grade = 3 Common Terminology Criteria for Adverse Events, version 5.0 (CTCAE v5.0) Up to 6 months
Primary Subject incidence of laboratory abnormalities Detection of liver and renal function, electrocardiogram, routine blood examination etc. Up to 1 month
Primary Systemic Immune Response Detection of increased systemic immune Response markers in sera (IL2,IL4,IL6,IL8,IL10,TNFa,IFN?, etc.) and peripheral blood mononuclear cells by multi-Color fluorescence-activated cell sorting (FACS) Up to 6 months
Secondary Disease Assessment for Disease Control Rate Evaluate the efficacy endpoints of DCR by the investigator with RECIST v1.1 and iRECIST Every 10 weeks for 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2